Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental.
Antidepressive Agents
/ therapeutic use
Biological Psychiatry
/ methods
Depressive Disorder, Major
/ epidemiology
Depressive Disorder, Treatment-Resistant
/ epidemiology
Expert Testimony
/ methods
Female
Foundations
/ standards
France
/ epidemiology
Humans
Male
Practice Guidelines as Topic
/ standards
Psychiatry
/ methods
Psychopharmacology
/ methods
Antidepressants
Expert consensus guidelines
Major depressive disorder
Pharmacotherapy
Treatment resistant depression
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
28 08 2019
28 08 2019
Historique:
received:
08
08
2018
accepted:
12
08
2019
entrez:
29
8
2019
pubmed:
29
8
2019
medline:
29
4
2020
Statut:
epublish
Résumé
Clear guidance for successive antidepressant pharmacological treatments for non-responders in major depression is not well established. Based on the RAND/UCLA Appropriateness Method, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of treatment-resistant depression. The expert guidelines combine scientific evidence and expert clinicians' opinions to produce recommendations for treatment-resistant depression. A written survey comprising 118 questions related to highly-detailed clinical presentations was completed on a risk-benefit scale ranging from 0 to 9 by 36 psychiatrist experts in the field of major depression and its treatments. Key-recommendations are provided by the scientific committee after data analysis and interpretation of the results of the survey. The scope of these guidelines encompasses the assessment of pharmacological resistance and situations at risk of resistance, as well as the pharmacological and psychological strategies in major depression. The expert consensus guidelines will contribute to facilitate treatment decisions for clinicians involved in the daily assessment and management of treatment-resistant depression across a number of common and complex clinical situations.
Sections du résumé
BACKGROUND
Clear guidance for successive antidepressant pharmacological treatments for non-responders in major depression is not well established.
METHOD
Based on the RAND/UCLA Appropriateness Method, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of treatment-resistant depression. The expert guidelines combine scientific evidence and expert clinicians' opinions to produce recommendations for treatment-resistant depression. A written survey comprising 118 questions related to highly-detailed clinical presentations was completed on a risk-benefit scale ranging from 0 to 9 by 36 psychiatrist experts in the field of major depression and its treatments. Key-recommendations are provided by the scientific committee after data analysis and interpretation of the results of the survey.
RESULTS
The scope of these guidelines encompasses the assessment of pharmacological resistance and situations at risk of resistance, as well as the pharmacological and psychological strategies in major depression.
CONCLUSION
The expert consensus guidelines will contribute to facilitate treatment decisions for clinicians involved in the daily assessment and management of treatment-resistant depression across a number of common and complex clinical situations.
Identifiants
pubmed: 31455302
doi: 10.1186/s12888-019-2237-x
pii: 10.1186/s12888-019-2237-x
pmc: PMC6712810
doi:
Substances chimiques
Antidepressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
262Références
J Psychiatr Res. 2009 Jan;43(3):205-14
pubmed: 18586273
Pharmacopsychiatry. 1989 Jan;22(1):21-5
pubmed: 2710808
Acta Psychiatr Scand. 1997 Apr;95(4):288-96
pubmed: 9150822
J Affect Disord. 2016 Jan 1;189:224-32
pubmed: 26451508
Pharmacopsychiatry. 2011 Sep;44(6):195-235
pubmed: 21969060
Int J Neuropsychopharmacol. 2015 May 25;18(11):pyv060
pubmed: 26012350
Am J Psychiatry. 2009 Sep;166(9):980-91
pubmed: 19687129
J Clin Psychopharmacol. 2011 Aug;31(4):512-6
pubmed: 21694617
Can J Psychiatry. 2016 Sep;61(9):524-39
pubmed: 27486150
J Psychopharmacol. 2014 Feb;28(2):85-98
pubmed: 24108407
Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):387-400
pubmed: 15868067
Eur Neuropsychopharmacol. 2009 Jul;19(7):457-65
pubmed: 19345072
Acta Psychiatr Scand Suppl. 2005;(428):25-31, 36
pubmed: 16307617
J Clin Psychiatry. 2011 Oct;72(10):1405-12
pubmed: 21367355
Can J Psychiatry. 2016 Sep;61(9):540-60
pubmed: 27486148
Mol Psychiatry. 2016 Apr;21(4):523-30
pubmed: 25917369
J Clin Psychiatry. 2007 Jul;68(7):1062-70
pubmed: 17685743
Acta Psychiatr Scand. 2005 Dec;112(6):425-33
pubmed: 16279871
World J Biol Psychiatry. 2013 Jul;14(5):334-85
pubmed: 23879318
Psychol Med. 2019 Feb;49(3):366-379
pubmed: 30139408
Encephale. 2010 Mar;36 Suppl 4:S79-85
pubmed: 21185426
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
Curr Med Res Opin. 2007 Feb;23(2):333-41
pubmed: 17288688
Eur Neuropsychopharmacol. 2016 Dec;26(12):1960-1971
pubmed: 27816317
Dtsch Arztebl Int. 2010 Oct;107(40):700-8
pubmed: 21031129
CNS Spectr. 2005 Oct;10(10):800-5
pubmed: 16400242
Encephale. 2013 Dec;39 Suppl 4:189-203
pubmed: 24373464
Am J Psychiatry. 2006 Jan;163(1):28-40
pubmed: 16390886
Biol Psychiatry. 2008 Apr 1;63(7):699-704
pubmed: 17919460
J Affect Disord. 2012 Jul;139(2):172-80
pubmed: 22381955
Neuropsychopharmacology. 2006 Sep;31(9):1841-53
pubmed: 16794566
J Psychopharmacol. 2015 May;29(5):459-525
pubmed: 25969470
Acta Psychiatr Scand Suppl. 2013;(443):6-23
pubmed: 23586873
Am J Psychiatry. 2006 Sep;163(9):1519-30; quiz 1665
pubmed: 16946176
Ann Intern Med. 2007 Nov 6;147(9):593-602
pubmed: 17975181
Depress Anxiety. 2002;16(4):162-71
pubmed: 12497648
J Clin Psychiatry. 2007 Jun;68(6):935-40
pubmed: 17592920
J Affect Disord. 2014 Oct;168:269-75
pubmed: 25069082
J Clin Psychiatry. 2015 Apr;76(4):e487-98
pubmed: 25919841
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
Int Clin Psychopharmacol. 2001 May;16(3):137-43
pubmed: 11354235
BMC Psychiatry. 2019 Jan 30;19(1):50
pubmed: 30700272
J Affect Disord. 2015 Jan 15;171:137-41
pubmed: 25305428
Psychopharmacol Bull. 1989;25(1):71-9
pubmed: 2672072
Am J Psychiatry. 2016 Feb 1;173(2):174-83
pubmed: 26552940